StockWatch
·

Research Reports

17 Aug 2026
GPTHEALTHGPT Healthcare Ltd

Beat YoY growth, but sequential PAT decline signals momentum loss

specialty mix ARPOB · Raipur unprofitable · sequential decline

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
SHILPAMEDSHILPA MEDICARE LTD.

The ₹28 Crore Mask: Transformation Real, Execution Risky

earnings · transformation · CDMO

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
SHILPAMEDSHILPA MEDICARE LTD.

Strong topline, margin compression, pipeline-rich transformation story

CDMO · Formulation launches · Biologics scaling

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
INNOVACAPInnova Captab Ltd

Volume Beat, Guidance Held — the Jammu Story Stays Multi-Year

CDMO · Jammu facility · volume growth

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
INNOVACAPInnova Captab Ltd

Volume target hit, margins stable, Jammu ramp on track

volume growth · CDMO demand · Jammu ramp

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
HIKALHIKAL LTD.

Recovery On Track, But Leverage and Crop Headwinds Cloud the Outlook

FDA remediation · leverage drag · Pharma CDMO

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
HIKALHIKAL LTD.

Pharma recovery on track; near-term earnings under pressure

FDA remediation · Animal Health scaling · CDMO partnerships

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
AARTIDRUGSAARTI DRUGS LTD.

Revenue up 19%, profit down 7%: the pricing illusion

pricing power · volume miss · capacity ramp

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
AARTIDRUGSAARTI DRUGS LTD.

Pricing surge masks weak volume; margin gains at risk if war-driven tailwinds fade

pricing power · capacity ramp-up · volume miss

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
HCGHealthCare Global Enterprises Ltd

Margin beat hinges on mix, not pricing — ARPP stalls at +2%

HCG · oncology · ARPP stagnation

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
HCGHealthCare Global Enterprises Ltd

Strong margins, volume-driven growth, strategic clarity—but ARPP weakness and new-hospital drag remain

payor mix · EBITDA margin expansion · volume growth

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
VIJAYAVijaya Diagnostic Centre Ltd

The ₹190 Crore Question: Execution Strong, But Capex Tests Margins

diagnostics · capex expansion · tier-2

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
VIJAYAVijaya Diagnostic Centre Ltd

Strong execution, capex raised on expansion confidence

network expansion · margin resilience · B2C leverage

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
16 Aug 2026
SUDEEPPHRMSudeep Pharma Ltd

Strong Growth, Margin Recovery Postponed

revenue growth · margin recovery · battery materials

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
SUDEEPPHRMSudeep Pharma Ltd

Strong revenue momentum offset by near-term margin compression

PFN 31% growth · battery materials · greenfield Q3

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
COHANCESuven Pharmaceuticals Ltd

Guided low, delivered loss. Recovery path unclear.

CDMO · ADC · oligonucleotides

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
COHANCESuven Pharmaceuticals Ltd

Guided miss: execution on plan, but NJ Bio drag and vague recovery timeline crimp credibility

NJ Bio drag · Phase 3 conversions · Sapala growth

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
KIMSKrishna Institute of Medical Sciences Ltd

Revenue surges 35%, profit plunges 56%—the new-unit reckoning

margin compression · new unit ramp · PAT cliff

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
KIMSKrishna Institute of Medical Sciences Ltd

Volume boom masks 56% PAT cliff; new units ramp, execution risks linger

new unit ramp · margin pressure · debt reduction

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
ASTERDMAster DM Healthcare Ltd

Revenue surge masks profit collapse as merger integration costs hit

merger-integration · synergies-pending · margin-compression

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
ASTERDMAster DM Healthcare Ltd

Revenue +21.6%, but PAT crashed 68.7% due to ₹114Cr merger costs

merger-integration · synergies-pending · margin-compression

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
SANOFISanofi India Ltd

Diabetes roars, partnerships stall—and the street is unconvinced

diabetes franchise · public sector expansion · partnership drag

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
SANOFISanofi India Ltd

Diabetes surge offset by partnership drag; margins intact but outlook hedged

diabetes leadership · public sector expansion · partnership volatility

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
MEDANTAGlobal Health Ltd

Volume boom, profit stuck — and management won't say when that changes

margin compression · Noida ramp-up · greenfield execution

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
MEDANTAGlobal Health Ltd

Strong volume growth masks margin pressure; Noida ahead of plan

volume growth · Noida ramp-up · margin compression

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
NHNarayana Hrudayalaya Ltd

78% revenue growth, 5% profit—the integrated care thesis works, but it's not profitable yet

integrated care model · margin compression · insurance losses

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
NHNarayana Hrudayalaya Ltd

Revenue 78% YoY but profit +5%—margin compression masks growth momentum

integrated care model · margin expansion · insurance losses

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
FORTISFORTIS HEALTHCARE LTD.

17.5% Revenue Growth Can't Mask 2.3% Profit Growth — Margin Compression and Guidance Delays

margin compression · PAT growth lag · ESOP charge

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
FORTISFORTIS HEALTHCARE LTD.

Strong revenue growth masked by margin compression and guidance delays

ESOP alignment · new unit ramp-up · oncology pricing headwind

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
GLAXOGLAXOSMITHKLINE PHARMACEUTICALS LTD.

Strong YoY growth masks Q1 sequential weakness; innovation pipeline credible but early-stage

portfolio transformation · innovation 7% · Shingrix 65%

TranscriptDeep diveQ1 FY276 minPharma & Healthcare